Drug Profile


Alternative Names: AIC-316; BAY 57-1293

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Bayer
  • Developer AiCuris
  • Class Antivirals; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action DNA helicase-primase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Herpes simplex virus infections

Highest Development Phases

  • Phase II Herpes labialis; Herpes simplex virus type 2 infections
  • Phase I Herpes simplex virus infections

Most Recent Events

  • 10 Mar 2017 AiCuris plans the PRIOH-1 phase II trial for Herpes simplex virus infections (NCT03073967)
  • 01 Nov 2016 Phase-II clinical trials in Herpes labialis in USA (Topical) (NCT02871492)
  • 06 Sep 2016 Phase-I clinical trials in Herpes simplex virus infections (Topical) before September 2016 (AiCuris pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top